Adriana Luk

Adriana Luk

Auto-generated profile, based on publicly available information

Adriana Luk

Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2013 in ISRN Biomaterials
Verified
Journal Article
Open access
PDF file
PSPooja Singhal
Pooja Singhal
ALAdriana Luk
Adriana Luk
JBJagdish Butany
Jagdish Butany
Prosthetic heart valves are commonly used in the treatment of valvular heart disease. Mechanical valves are more durable than the bioprosthetic valves; however, the need for long-term anticoagulant therapy renders them unsuitable for some patient groups. In this paper we discuss the different types and models of bioprosthesis, and in particular, pericardial bioprosthesis. We also discuss the preimplantation preparation processes, as well as their postimplantation changes and modes of failure.

10 July 2022 in European Journal of Heart Failure
Verified
Journal Article
Closed access
FSFernando L. Scolari
Fernando L. Scolari
SASagi Abelson
Sagi Abelson
.B. Darshan H. Brahmbhatt
. Darshan H. Brahmbhatt
JMJessie J.F. Medeiros
Jessie J.F. Medeiros
CFChun‐Po S. Fan
Chun‐Po S. Fan
PBPhyllis Billia
Phyllis Billia

1 October 2021 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
ALAdriana Luk
Adriana Luk
BCBrian Clarke
Brian Clarke
NDNagib Dahdah
Nagib Dahdah
ADAnique Ducharme
Anique Ducharme
AKAndrew Krahn
Andrew Krahn
MMMichael McDonald
Michael McDonald

1 July 2020 in CJC Open
Verified
Journal Article
Open access
JCJustin Chow
Justin Chow
AAAnhar Alhussaini
Anhar Alhussaini
OCOscar Calvillo-Argüelles
Oscar Calvillo-Argüelles
FBFilio Billia
Filio Billia
ALAdriana Luk
Adriana Luk
Coronavirus Disease 2019 (COVID-19) has been associated with cardiovascular complications, including acute cardiac injury, heart failure, and cardiogenic shock (CS). The role of venoarterial extracorporeal membrane oxygenation (VA-ECMO) in the event of COVID-19–associated cardiovascular collapse has not been established. We reviewed the existing literature surrounding the role of VA-ECMO in the treatment of coronavirus-related cardiovascular collapse. COVID-19 is associated with a higher incidence of cardiovascular complications compared with previous coronavirus outbreaks (Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus). We found only 1 case report from China in which COVID-19–associated fulminant myocarditis and CS were successfully rescued using VA-ECMO as a bridge to recovery. We identified potential clinical scenarios (cardiac injury, myocardial infarction with and without obstructive coronary artery disease, viral myocarditis, and decompensated heart failure) leading to CS and risk factors for poor/uncertain benefit (age, sepsis, mixed/predominantly vasodilatory shock, prothrombotic state or coagulopathy, severe acute respiratory distress syndrome, multiorgan failure, or high-risk prognostic scores) specific to using VA-ECMO as a bridge to recovery in COVID-19 infection. Additional considerations and proposed recommendations specific to the COVID-19 pandemic were formulated with guidance from published data and expert consensus. A small subset of patients with cardiovascular complications from COVID-19 infection may progress to refractory CS. While accepting that resource scarcity may be the overwhelming concern for healthcare systems during this pandemic, VA-ECMO can be considered in highly selected cases of refractory CS and echocardiographic evidence of biventricular failure. The decision to initiate this therapy should take into consideration the availability of resources, perceived benefit, and risks of transmitting disease.

16 August 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
FSFernando L. Scolari
Fernando L. Scolari
.B. Darshan H. Brahmbhatt
. Darshan H. Brahmbhatt
SASagi Abelson
Sagi Abelson
JMJessie J.F. Medeiros
Jessie J.F. Medeiros
Markus S. AnkerMarkus S. Anker
Markus S. Anker
PBPhyllis Billia
Phyllis Billia
Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing was used to detect CH-associated mutations. We evaluated the association between CH and acute cellular rejection, CMV infection, cardiac allograft vasculopathy (CAV), malignancies, and survival. CH mutations were detected in 26 (20.5%) patients, mostly in DNMT3A, ASXL1, and TET2. Patients with CH showed a higher frequency of CAV grade 2 or 3 (0% vs. 18%, p < .001). Moreover, a higher mortality rate was observed in patients with CH (11 [42%] vs. 15 [15%], p = .008) with an adjusted hazard ratio of 2.9 (95% CI, 1.4-6.3; p = .003). CH was not associated with acute cellular rejection, CMV infection or malignancies. The prevalence of CH in OHT recipients is higher than previously reported for the general population of the same age group, with an associated higher prevalence of CAV and mortality.

15 June 2023 in ESC Heart Failure
Verified
Journal Article
Open access
EREduard Rodenas-Alesina
Eduard Rodenas-Alesina
FSFernando Luis Scolari
Fernando Luis Scolari
VWVicki N. Wang
Vicki N. Wang
DBDarshan H. Brahmbhatt
Darshan H. Brahmbhatt
VMVesna Mihajlovic
Vesna Mihajlovic
ALAdriana Luk
Adriana Luk
Aims: Studies in cardiogenic shock (CS) often have a heterogeneous population of patients, including those with acute myocardial infarction and acute decompensated heart failure (ADHF-CS). The therapeutic profile of milrinone may benefit patients with ADHF-CS. We compared the outcomes and haemodynamic trends in ADHF-CS receiving either milrinone or dobutamine. Methods and results: Patients presenting with ADHF-CS (from 2014 to 2020) treated with a single inodilator (milrinone or dobutamine) were included in this study. Clinical characteristics, outcomes, and haemodynamic parameters were collected. The primary endpoint was 30 day mortality, with censoring at the time of transplant or left ventricular assist device implantation. A total of 573 patients were included, of which 366 (63.9%) received milrinone and 207 (36.1%) received dobutamine. Patients receiving milrinone were younger, had better kidney function, and lower lactate at admission. In addition, patients receiving milrinone received mechanical ventilation or vasopressors less frequently, whereas a pulmonary artery catheter was more frequently used. Milrinone use was associated with a lower adjusted risk of 30 day mortality (hazard ratio = 0.52, 95% confidence interval 0.35–0.77). After propensity-matching, the use of milrinone remained associated with a lower mortality (hazard ratio = 0.51, 95% confidence interval 0.27–0.96). These findings were associated with improved pulmonary artery compliance, stroke volume, and right ventricular stroke work index. Conclusions: The use of milrinone compared with dobutamine in patients with ADHF-CS is associated with lower 30 day mortality and improved haemodynamics. These findings warrant further study in future randomized controlled trials.